ehc-20220801
false000078516100007851612022-08-012022-08-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): August 1, 2022
Encompass Health Corporation
(Exact name of Registrant as specified in its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
001-1031563-0860407
(Commission File Number)(IRS Employer Identification No.)
9001 Liberty Parkway, Birmingham, Alabama 35242
(Address of Principal Executive Offices, Including Zip Code)
(205) 967-7116
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.     Emerging growth company   ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareEHCNew York Stock Exchange


The information contained herein is being furnished pursuant to Item 2.02 of Form 8‑K, “Results of Operations and Financial Condition,” and Item 7.01 of Form 8-K, “Regulation FD Disclosure.” This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
ITEM 2.02. Results of Operations and Financial Condition.
    On August 1, 2022, Encompass Health Corporation (“Encompass Health” or the “Company”) issued a press release reporting the financial results of the Company for the three and six months ended June 30, 2022. A copy of the press release is attached to this report as Exhibit 99.1 and incorporated herein by reference.
    The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on hospitals open throughout both the full current and prior periods presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company's results of operations.
ITEM 7.01. Regulation FD Disclosure.
See Item 2.02, “Results of Operations and Financial Condition,” above.
In addition, a copy of the supplemental information which will be discussed during the Company’s earnings call at 10:00 a.m. Eastern Time on Tuesday, August 2, 2022 is attached to this report as Exhibit 99.2 and incorporated herein by reference.
Note Regarding Presentation of Non-GAAP Financial Measures
The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company’s adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow.
The Company is providing adjusted earnings per share from continuing operations attributable to Encompass Health (“adjusted earnings per share”). The Company believes the presentation of adjusted earnings per share provides useful additional information to investors because it provides better comparability of ongoing operating performance to prior periods given that it excludes the impact of government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging and equity instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be non-indicative of its ongoing operating performance. It is reasonable to expect that one or more of these excluded items will occur in future periods, but the amounts recognized can vary significantly from period to period and may not directly relate to the Company’s ongoing operating performance. Accordingly, they can complicate comparisons of the Company’s results of operations across periods and comparisons of the Company’s results to those of other healthcare companies. Adjusted earnings per share should not be considered as a measure of financial performance under generally accepted accounting principles in the United States (“GAAP”) as the items excluded from it are significant components in understanding and assessing financial performance. Because adjusted earnings per share is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies. The Company reconciles adjusted earnings per share to earnings per share in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2.
The leverage ratio referenced therein is defined as the ratio of consolidated total debt to Adjusted EBITDA for the trailing four quarters. The Company believes its leverage ratio and Adjusted EBITDA are measures of its ability to service its debt and its ability to make capital expenditures. Additionally, the leverage ratio is a standard measurement used by investors to gauge the creditworthiness of an institution. The Company’s credit agreement also includes a maximum leverage ratio financial covenant which allows the Company to deduct up to $300 million of cash on hand from consolidated total debt. The Company reconciles Adjusted EBITDA to net income and to net cash provided by operating activities in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2. Adjusted EBITDA for the Company’s reportable segments is reconciled to net income from continuing operations before income tax expense in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2.


The Company uses Adjusted EBITDA on a consolidated basis as a liquidity measure. The Company believes this financial measure on a consolidated basis is important in analyzing its liquidity because it is the key component of certain material covenants contained within the Company’s credit agreement, which is discussed in more detail in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, “Liquidity and Capital Resources,” and Note 10, Long-term Debt, to the consolidated financial statements included in its Annual Report on Form 10‑K for the year ended December 31, 2021 (the “2021 Form 10‑K”). These covenants are material terms of the credit agreement. Noncompliance with these financial covenants under the credit agreement—its interest coverage ratio and its leverage ratio—could result in the Company’s lenders requiring the Company to immediately repay all amounts borrowed. If the Company anticipated a potential covenant violation, it would seek relief from its lenders, which would have some cost to the Company, and such relief might be on terms less favorable to those in the Company’s existing credit agreement. In addition, if the Company cannot satisfy these financial covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying common stock dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the Company’s assessment of its liquidity.
In general terms, the credit agreement definition of Adjusted EBITDA, therein referred to as “Adjusted Consolidated EBITDA,” allows the Company to add back to consolidated net income interest expense, income taxes, and depreciation and amortization and then add back to consolidated net income (1) all unusual or nonrecurring items reducing consolidated net income (of which only up to $10 million in a year may be cash expenditures), (2) any losses from discontinued operations, (3) non-ordinary course fees, costs and expenses incurred with respect to any litigation or settlement, (4) share-based compensation expense, (5) costs and expenses associated with changes in the fair value of marketable securities, (6) costs and expenses associated with the issuance or prepayment debt and acquisitions, and (7) any restructuring charges not in excess of 20% of Adjusted Consolidated EBITDA. The Company also subtracts from consolidated net income all unusual or nonrecurring items to the extent they increase consolidated net income.
The calculation of Adjusted EBITDA under the credit agreement does not require us to deduct net income attributable to noncontrolling interests or gains on fair value adjustments of hedging and equity instruments, disposal of assets, and development activities. It also does not allow us to add back losses on fair value adjustments of hedging instruments or unusual or nonrecurring cash expenditures in excess of $10 million. These items and amounts, in addition to the items falling within the credit agreement’s “unusual or nonrecurring” classification, may occur in future periods, but can vary significantly from period to period and may not directly relate to, or be indicative of, the Company's ongoing liquidity or operating performance. Accordingly, the Adjusted EBITDA calculation presented here includes adjustments for them.
Adjusted EBITDA is not a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for net income or cash flows from operating, investing, or financing activities. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note 1, Summary of Significant Accounting Policies, to the consolidated financial statements accompanying the 2021 Form 10-K.
The Company also uses adjusted free cash flow as an analytical indicator to assess its performance. Management believes the presentation of adjusted free cash flow provides investors an efficient means by which they can evaluate the Company’s capacity to reduce debt, pursue development activities, and return capital to its common stockholders. The calculation of adjusted free cash flow and a reconciliation of net cash provided by operating activities to adjusted free cash flow are included in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2. This measure is not a defined measure of financial performance under GAAP and should not be considered as an alternative to net cash provided by operating activities. The Company’s definition of adjusted free cash flow is limited and does not represent residual cash flows available for discretionary spending. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. See the consolidated statements of cash flows included in the 2021 Form 10-K and the condensed consolidated statements of cash flows included in the Company's quarterly report on Form 10-Q for the quarterly period ended June 30, 2022 (the “June 2022 Form 10-Q”), when filed, and in the press release attached as Exhibit 99.1 for the GAAP measures of cash flows from operating, investing, and financing activities.


Forward-Looking Statements
The information contained in the press release and supplemental information includes certain estimates, projections, and other forward-looking statements that involve known and unknown risks and relate to, among other things, future events, including the impact of the spin off of Enhabit, Inc. on the business model, outlook and guidance, the expected impact of the COVID-19 pandemic on Encompass Health’s business and financial assumptions, the Company’s business strategy, financial plans, dividend strategies or payments, effective income tax rates, plans to repurchase its debt or equity securities, future financial performance, projected business results or model, ability to return value to its shareholders, projected capital expenditures and development plans, leverage ratio, acquisition opportunities, and the impact of future legislation or regulation. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “targets,” “potential,” or “continue” or the negative of these terms or other comparable terminology. These estimates, projections, and other forward-looking statements are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual results, and those differences may be material.
There can be no assurance that any estimates, projections, or forward-looking statements will be realized.
All such estimates, projections, and forward-looking statements speak only as of the date hereof. The Company undertakes no duty to publicly update or revise that information.
You are cautioned not to place undue reliance on the estimates, projections, and other forward-looking statements in this report, the press release, and supplemental information as they are based on current expectations and general assumptions and are subject to various risks, uncertainties, and other factors, including those set forth in the attached press release and in the 2021 Form 10‑K, the June 2022 Form 10-Q when filed, and in other documents the Company previously filed with the SEC, many of which are beyond the Company’s control. These factors may cause actual results to differ materially from the views, beliefs, and estimates expressed herein.
ITEM 9.01. Financial Statements and Exhibits.
(d)    Exhibits.
Exhibit NumberDescription
104Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
ENCOMPASS HEALTH CORPORATION
By:
/S/   DOUGLAS E. COLTHARP
Name:Douglas E. Coltharp
Title:Executive Vice President and Chief Financial Officer
Dated: August 1, 2022

Exhibit 99.1
Media ContactAugust 1, 2022
Casey Winger, 205 447-6410
[email protected]
Investor Relations Contact
Mark Miller, 205 970-5860
[email protected]
Encompass Health reports results for second quarter 2022

BIRMINGHAM, Ala. - Encompass Health Corporation (NYSE: EHC), the largest owner and operator of inpatient rehabilitation hospitals in the United States, today reported its results of operations for the second quarter ended June 30, 2022 and affirmed its 2022 guidance.
“Our second quarter results are further evidence of the strong demand for our inpatient rehabilitation services,” said President and Chief Executive Officer of Encompass Health Mark Tarr. “Second quarter discharge growth was 4.9%, on top of 18.7% discharge growth in the second quarter of 2021. While we continue to face near-term staffing challenges, we remain confident in the long-term prospects for our business.”
On July 1, 2022, Encompass Health completed the spin off of Enhabit Home Health & Hospice (“Enhabit”), which is now an independent, publicly traded company. Enhabit’s second quarter results are required to be in this earnings release, but no commentary on those results is included herein. Beginning with the third quarter of 2022, Enhabit’s historical results will be reported in Encompass Health’s discontinued operations.


1

Consolidated results
Growth
Q2 2022Q2 2021DollarsPercent
(In Millions, Except Per Share Data)
Net operating revenues$1,330.5 $1,287.7 $42.8 3.3 %
Income from continuing operations attributable to Encompass Health per diluted share
0.49 1.13 (0.64)(56.6)%
Adjusted earnings per share0.89 1.17 (0.28)(23.9)%
Cash flows provided by operating activities
244.6 255.9 (11.3)(4.4)%
Adjusted EBITDA240.2 278.9 (38.7)(13.9)%
Adjusted free cash flow205.7 205.6 0.1 — %
Six Months Ended June 30,
20222021
Cash flows provided by operating activities
$463.5 $414.4 $49.1 11.8 %
Adjusted free cash flow371.6 313.0 58.6 18.7 %
See attached supplemental information for calculations of non-GAAP measures and reconciliations to their most comparable GAAP measure.
General and administrative expenses
Q2 2022% of Consolidated RevenueQ2 2021% of Consolidated Revenue
(In Millions)
General and administrative expenses, excluding stock-based compensation
$28.6 2.1%$36.8 2.9%
General and administrative expenses decreased as a percent of consolidated revenue due to improved operating leverage, a decline in the mark-to-market value of the Company’s nonqualified 401(k) plan, and lower incentive compensation in Q2 2022.
General and administrative expenses in the above table exclude $22.9 million and $4.1 million in costs associated with the strategic alternatives review of the Company’s home health and hospice business for the second quarter of 2022 and the second quarter of 2021, respectively.


2


Inpatient rehabilitation segment results
Growth
Q2 2022Q2 2021DollarsPercent
Net operating revenues:(In Millions)
Inpatient
$1,037.8 $976.9 $60.9 6.2 %
Outpatient and other
24.7 24.7 — — %
Total segment revenue
$1,062.5 $1,001.6 $60.9 6.1 %
(Actual Amounts)
Discharges51,902 49,492 2,410 4.9 %
Same-store discharge growth
1.6 %
Net patient revenue per discharge$19,995 $19,739 $256 1.3 %
Revenue reserves related to bad debt as a percent of revenue
2.2 %1.7 %50 bps
(In Millions)
Adjusted EBITDA$225.0 $254.0 $(29.0)(11.4)%
•Revenue – Inpatient revenue growth resulted from increased volumes and pricing. Total discharge growth for the second quarter of 2022 was 4.9% with same-store growth of 1.6%. Revenue reserves related to bad debt as a percent of revenue increased 50 basis points, primarily attributable to a shift in payor mix toward non-Medicare payors.
Growth in net patient revenue per discharge of 1.3% primarily resulted from an increase in reimbursement rates, partially offset by the resumption of sequestration.
Outpatient and other revenue was unchanged.
•Adjusted EBITDA – The 11.4% decrease in Adjusted EBITDA primarily resulted from increased utilization and pricing of agency staffing and sign-on and shift bonuses.
Home health and hospice segment results
Growth
Q2 2022Q2 2021DollarsPercent
Net operating revenues:(In Millions)
Home health
$220.2 $232.3 $(12.1)(5.2)%
Hospice
47.8 53.8 (6.0)(11.2)%
Total segment revenue
$268.0 $286.1 $(18.1)(6.3)%
Adjusted EBITDA$43.8 $61.7 $(17.9)(29.0)%
Please refer to Enhabit’s Q2 2022 earnings materials filed separately today.

3


2022 guidance
The Company is affirming its guidance for its ongoing inpatient rehabilitation business for full-year 2022.
2022 Guidance Ranges
(In Millions, Except Per Share Data)
Net operating revenues$4,250 to $4,300
Adjusted EBITDA$820 to $840
Adjusted earnings per share from continuing operations attributable to Encompass Health
$2.77 to $2.91
For considerations regarding the Company’s 2022 guidance ranges, see the supplemental information posted on the Company’s website at http://investor.encompasshealth.com. See also the “Other information” section below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share.
Earnings conference call and webcast
The Company will host an investor conference call at 10:00 a.m. Eastern Time on Tuesday, August 2, 2022 to discuss its results for the second quarter of 2022. For reference during the call, the Company will post certain supplemental information at http://investor.encompasshealth.com.
The conference call may be accessed by dialing 866 342-8591 and giving the pass code EHCQ222. International callers should dial 203 518-9713 and give the same pass code. Please call approximately ten minutes before the start of the call to ensure you are connected. The conference call will also be webcast live and will be available for on-line replay at http://investor.encompasshealth.com by clicking on an available link.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 150 hospitals in 35 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's 100 Best Companies to Work For. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.
Other information
The information in this press release is summarized and should be read in conjunction with the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 (the “June 2022 Form 10-Q”), when filed, as well as the Company’s Current Report on Form 8-K filed on August 1, 2022 (the “Q2 Earnings Form 8-K”), to which this press release is attached as Exhibit 99.1. In addition, the Company will post supplemental information today on its website at http://investor.encompasshealth.com for reference during its August 2, 2022 earnings call.
The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company’s adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow. Reconciliations to their most comparable GAAP measure, except with regard to non-GAAP guidance, are included below or in the Q2 Earnings Form 8-K. Readers are encouraged to review the “Note Regarding Presentation of Non-GAAP Financial Measures” included in the Q2 Earnings Form 8-K which provides further explanation and disclosure regarding the Company’s use of these non-GAAP financial measures.
4

Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise not indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be not indicative of its ongoing operations. These items cannot be reasonably predicted and will depend on several factors, including industry and market conditions, and could be material to the Company’s results computed in accordance with GAAP.
However, the following reasonably estimable GAAP measures for 2022 would be included in a reconciliation for Adjusted EBITDA if the other reconciling GAAP measures could be reasonably predicted:
•Interest expense and amortization of debt discounts and fees - estimate of $160 million to $170 million
•Amortization of debt-related items - approximately $10 million
The Q2 Earnings Form 8-K and, when filed, the June 2022 Form 10-Q can be found on the Company’s website at http://investor.encompasshealth.com and the SEC's website at www.sec.gov.
5
Encompass Health Corporation and Subsidiaries
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
Three Months Ended June 30,Six Months Ended June 30,
 2022202120222021
(In Millions, Except Per Share Data)
Net operating revenues$1,330.5 $1,287.7 $2,664.1 $2,518.1 
Operating expenses:
Salaries and benefits773.8 708.2 1,549.8 1,395.4 
Other operating expenses193.4 172.7 375.5 335.0 
Occupancy costs19.3 20.2 40.2 40.4 
Supplies52.8 50.0 108.9 101.9 
General and administrative expenses60.3 54.2 108.7 92.8 
Depreciation and amortization68.8 63.4 135.0 125.9 
Total operating expenses1,168.4 1,068.7 2,318.1 2,091.4 
Loss on early extinguishment of debt1.1 1.0 1.4 1.0 
Interest expense and amortization of debt discounts and fees60.6 41.8 100.2 84.6 
Other expense (income)6.3 (4.6)9.9 (6.0)
Equity in net income of nonconsolidated affiliates(1.0)(1.0)(1.9)(2.0)
Income from continuing operations before income tax expense95.1 181.8 236.4 349.1 
Provision for income tax expense23.8 39.5 55.0 74.0 
Income from continuing operations71.3 142.3 181.4 275.1 
Loss from discontinued operations, net of tax— (0.3)— (0.3)
Net and comprehensive income71.3 142.0 181.4 274.8 
Less: Net and comprehensive income attributable to
noncontrolling interests
(22.6)(28.7)(45.2)(54.2)
Net and comprehensive income attributable to
Encompass Health
$48.7 $113.3 $136.2 $220.6 
Weighted average common shares outstanding:  
Basic99.2 99.0 99.2 99.0 
Diluted100.3 100.2 100.2 100.2 
Earnings per common share:
Basic earnings per share attributable to Encompass Health common shareholders:
   
Continuing operations
$0.49 $1.14 $1.37 $2.22 
Discontinued operations
— — — — 
Net income
$0.49 $1.14 $1.37 $2.22 
Diluted earnings per share attributable to Encompass Health common shareholders:
Continuing operations
$0.49 $1.13 $1.36 $2.20 
Discontinued operations
— — — — 
Net income
$0.49 $1.13 $1.36 $2.20 
Amounts attributable to Encompass Health common shareholders: 
Income from continuing operations$48.7 $113.6 $136.2 $220.9 
Loss from discontinued operations, net of tax— (0.3)— (0.3)
Net income attributable to Encompass Health$48.7 $113.3 $136.2 $220.6 
6
Encompass Health Corporation and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited)
June 30, 2022December 31, 2021
 (In Millions)
Assets  
Current assets:  
Cash and cash equivalents$186.5 $54.8 
Restricted cash70.8 65.1 
Accounts receivable658.7 680.3 
Other current assets116.4 121.2 
Total current assets1,032.4 921.4 
Property and equipment, net2,730.1 2,601.6 
Operating lease right-of-use assets238.5 242.0 
Goodwill2,456.5 2,427.9 
Intangible assets, net398.4 417.5 
Other long-term assets226.3 254.5 
Total assets$7,082.2 $6,864.9 
Liabilities and Shareholders’ Equity
Current liabilities:  
Current portion of long-term debt$49.2 $42.8 
Current operating lease liabilities36.7 38.4 
Accounts payable138.3 137.6 
Accrued expenses and other current liabilities611.2 530.0 
Total current liabilities835.4 748.8 
Long-term debt, net of current portion3,233.5 3,243.9 
Long-term operating lease liabilities211.9 213.1 
Deferred income tax liabilities79.8 86.7 
Other long-term liabilities177.0 173.2 
 4,537.6 4,465.7 
Commitments and contingencies
Redeemable noncontrolling interests43.3 42.2 
Shareholders’ equity:  
Encompass Health shareholders’ equity2,003.0 1,911.3 
Noncontrolling interests498.3 445.7 
Total shareholders’ equity2,501.3 2,357.0 
Total liabilities and shareholders’ equity$7,082.2 $6,864.9 
7
Encompass Health Corporation and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(Unaudited)
 Six Months Ended June 30,
 20222021
 (In Millions)
Cash flows from operating activities:  
Net income$181.4 $274.8 
Loss from discontinued operations, net of tax— 0.3 
Adjustments to reconcile net income to net cash provided by operating activities—
  
Depreciation and amortization135.0 125.9 
Stock-based compensation16.3 14.8 
Deferred tax expense(7.9)6.2 
Other, net22.0 4.0 
Changes in assets and liabilities, net of acquisitions —  
Accounts receivable29.8 (38.1)
Other assets2.2 (17.2)
Accounts payable3.9 6.6 
Accrued payroll16.1 27.4 
Other liabilities64.7 10.3 
Net cash used in operating activities of discontinued operations— (0.6)
Total adjustments282.1 139.3 
Net cash provided by operating activities463.5 414.4 
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired— (97.7)
Purchases of property and equipment(230.0)(212.7)
Additions to capitalized software costs(4.9)(10.0)
Other, net(11.4)(1.2)
Net cash used in investing activities(246.3)(321.6)
Cash flows from financing activities:  
Principal borrowings on notes400.0 — 
Principal payments on debt, including pre-payments(345.2)(207.3)
Borrowings on revolving credit facility300.0 45.0 
Payments on revolving credit facility(330.0)— 
Principal payments under finance lease obligations(11.9)(11.8)
Debt amendment and issuance costs(25.0)— 
Taxes paid on behalf of employees for shares withheld(7.7)(16.4)
Contributions from noncontrolling interests of consolidated affiliates42.6 36.1 
Dividends paid on common stock(56.3)(56.9)
Distributions paid to noncontrolling interests of consolidated affiliates(46.6)(52.7)
Other, net(0.1)0.1 
Net cash used in financing activities(80.2)(263.9)
Increase (decrease) in cash, cash equivalents, and restricted cash137.0 (171.1)
Cash, cash equivalents. and restricted cash at beginning of period120.3 310.9 
Cash, cash equivalents, and restricted cash at end of period$257.3 $139.8 
8
Encompass Health Corporation and Subsidiaries
Supplemental Information
Earnings Per Share
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
(In Millions, Except Per Share Data)
Adjusted EBITDA$240.2 $278.9 $485.2 $529.7 
Depreciation and amortization
(68.8)(63.4)(135.0)(125.9)
Interest expense and amortization of debt discounts and fees
(60.6)(41.8)(100.2)(84.6)
Stock-based compensation(8.8)(12.0)(16.3)(14.8)
Loss on disposal or impairment of assets(2.3)(2.9)(2.9)(2.8)
99.7 158.8 230.8 301.6 
Items not indicative of ongoing operating performance:
Loss on early extinguishment of debt
(1.1)(1.0)(1.4)(1.0)
Costs associated with the strategic alternatives review(22.9)(4.1)(32.5)(5.0)
Costs associated with the Frontier acquisition— (1.3)— (1.3)
Change in fair market value of equity securities
(3.2)0.7 (5.7)0.6 
Pre-tax income72.5 153.1 191.2 294.9 
Income tax expense
(23.8)(39.5)(55.0)(74.0)
Income from continuing operations (1)
$48.7 $113.6 $136.2 $220.9 
Basic shares99.2 99.0 99.2 99.0 
Diluted shares100.3 100.2 100.2 100.2 
Basic earnings per share (1)
$0.49 $1.14 $1.37 $2.22 
Diluted earnings per share (1)
$0.49 $1.13 $1.36 $2.20 
(1)Income from continuing operations attributable to Encompass Health
9
Encompass Health Corporation and Subsidiaries
Supplemental Information
Adjusted Earnings Per Share

Q26 Months
2022202120222021
Earnings per share, as reported$0.49 $1.13 $1.36 $2.20 
Adjustments, net of tax:
Costs associated with the strategic alternatives review0.32 0.03 0.39 0.04 
Costs associated with the Frontier acquisition— 0.01 — 0.01 
Income tax adjustments
0.05 — 0.06 (0.03)
Loss on early extinguishment of debt
0.01 0.01 0.01 0.01 
Change in fair market value of equity securities
0.02 — 0.04 — 
Adjusted earnings per share*
$0.89 $1.17 $1.86 $2.22 
*    Adjusted EPS may not sum due to rounding.

10
Encompass Health Corporation and Subsidiaries
Supplemental Information
Adjusted Earnings Per Share

For the Three Months Ended June 30, 2022
Adjustments
As ReportedLoss on Early Extinguishment of DebtIncome Tax AdjustmentsCosts Associated with the Strategic Alternatives ReviewChange in Fair Market Value of Equity SecuritiesAs Adjusted
(In Millions, Except Per Share Amounts)
Adjusted EBITDA*$240.2 $— $— $— $— $240.2 
Depreciation and amortization(68.8)— — — — (68.8)
Interest expense and amortization of debt discounts and fees
(60.6)— — 20.5 — (40.1)
Stock-based compensation(8.8)— — — — (8.8)
Loss on disposal or impairment of assets(2.3)— — — — (2.3)
Loss on early extinguishment of debt
(1.1)1.1 — — — — 
Costs associated with the strategic alternatives review(22.9)— — 22.9 — — 
Change in fair market value of equity securities
(3.2)— — — 3.2 — 
Income from continuing operations before income tax expense
72.5 1.1 — 43.4 3.2 120.2 
Provision for income tax expense(23.8)(0.3)5.5 (11.3)(0.9)(30.8)
Income from continuing operations attributable to Encompass Health
$48.7 $0.8 $5.5 $32.1 $2.3 $89.4 
Diluted earnings per share from continuing operations**$0.49 $0.01 $0.05 $0.32 $0.02 $0.89 
Diluted shares used in calculation100.3 

*    Reconciliation to GAAP provided on page 15
**    Adjusted EPS may not sum across due to rounding.
11
Encompass Health Corporation and Subsidiaries
Supplemental Information
Adjusted Earnings Per Share

For the Three Months Ended June 30, 2021
Adjustments
As ReportedLoss on Early Exting. of DebtIncome Tax AdjustmentsCosts Associated with the Strategic Alternatives ReviewCosts Associated with the Frontier AcquisitionChange in Fair Market Value of Equity SecuritiesAs Adjusted
(In Millions, Except Per Share Amounts)
Adjusted EBITDA*$278.9 $— $— $— $— $— $278.9 
Depreciation and amortization(63.4)— — — — — (63.4)
Interest expense and amortization of debt discounts and fees
(41.8)— — — — — (41.8)
Stock-based compensation(12.0)— — — — — (12.0)
Loss on disposal or impairment of assets(2.9)— — — — — (2.9)
Loss on early extinguishment of debt(1.0)1.0 — — — — — 
Costs associated with the strategic alternatives review(4.1)— — 4.1 — — 
Costs associated with the Frontier Acquisition(1.3)— — — 1.3 — — 
Change in fair market value of equity securities
0.7 — — — — (0.7)— 
Income from continuing operations before income tax expense
153.1 1.0 — 4.1 1.3 (0.7)158.8 
Provision for income tax expense(39.5)(0.3)(0.1)(1.1)(0.3)0.2 (41.1)
Income from continuing operations attributable to Encompass Health
$113.6 $0.7 $(0.1)$3.0 $1.0 $(0.5)$117.7 
Diluted earnings per share from continuing operations**
$1.13 $0.01 $— $0.03 $0.01 $— $1.17 
Diluted shares used in calculation100.2 

*    Reconciliation to GAAP provided on page 15
**    Adjusted EPS may not sum across due to rounding.

12
Encompass Health Corporation and Subsidiaries
Supplemental Information
Adjusted Earnings Per Share

For the Six Months Ended June 30, 2022
Adjustments
As ReportedLoss on Early Extinguishment of DebtIncome Tax AdjustmentsCosts Associated with the Strategic Alternatives ReviewChange in Fair Market Value of Equity SecuritiesAs Adjusted
(In Millions, Except Per Share Amounts)
Adjusted EBITDA*$485.2 $— $— $— $— $485.2 
Depreciation and amortization(135.0)— — — — (135.0)
Interest expense and amortization of debt discounts and fees
(100.2)— — 20.5 — (79.7)
Stock-based compensation(16.3)— — — — (16.3)
Loss on disposal or impairment of assets(2.9)— — — — (2.9)
Loss on early extinguishment of debt
(1.4)1.4 — — — — 
Costs associated with the strategic alternatives review(32.5)— — 32.5 — — 
Change in fair market value of equity securities
(5.7)— — — 5.7 — 
Income from continuing operations before income tax expense
191.2 1.4 — 53.0 5.7 251.3 
Provision for income tax expense(55.0)(0.4)5.7 (13.8)(1.5)(65.0)
Income from continuing operations attributable to Encompass Health
$136.2 $1.0 $5.7 $39.2 $4.2 $186.3 
Diluted earnings per share from continuing operations**$1.36 $0.01 $0.06 $0.39 $0.04 $1.86 
Diluted shares used in calculation100.2 

*    Reconciliation to GAAP provided on page 15
**    Adjusted EPS may not sum across due to rounding.

13
Encompass Health Corporation and Subsidiaries
Supplemental Information
Adjusted Earnings Per Share

For the Six Months Ended June 30, 2021
Adjustments
As ReportedLoss on Early Exting. of DebtIncome Tax AdjustmentsCosts Associated with the Strategic Alternatives ReviewCosts Associated with the Frontier AcquisitionChange in Fair Market Value of Equity SecuritiesAs Adjusted
(In Millions, Except Per Share Amounts)
Adjusted EBITDA*$529.7 $— $— $— $— $— $529.7 
Depreciation and amortization(125.9)— — — — — (125.9)
Interest expense and amortization of debt discounts and fees
(84.6)— — — — — (84.6)
Stock-based compensation(14.8)— — — — — (14.8)
Loss on disposal or impairment of assets(2.8)— — — — — (2.8)
Loss on early extinguishment of debt(1.0)1.0 — — — — — 
Costs associated with the strategic alternatives review(5.0)— — 5.0 — — 
Costs associated with the Frontier Acquisition(1.3)— — — 1.3 — — 
Change in fair market value of equity securities
0.6 — — — — (0.6)— 
Income from continuing operations before income tax expense
294.9 1.0 — 5.0 1.3 (0.6)301.6 
Provision for income tax expense(74.0)(0.3)(3.4)(1.3)(0.3)0.2 (79.1)
Income from continuing operations attributable to Encompass Health
$220.9 $0.7 $(3.4)$3.7 $1.0 $(0.4)$222.5 
Diluted earnings per share from continuing operations**
$2.20 $0.01 $(0.03)$0.04 $0.01 $— $2.22 
Diluted shares used in calculation100.2 

*    Reconciliation to GAAP provided on page 15
**    Adjusted EPS may not sum across due to rounding.

14
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Net Income to Adjusted EBITDA

 Three Months Ended June 30,Six Months Ended June 30,
 2022202120222021
(In Millions)
Net income$71.3 $142.0 $181.4 $274.8 
Loss from discontinued operations, net of tax, attributable to Encompass Health— 0.3 — 0.3 
Net income attributable to noncontrolling interests(22.6)(28.7)(45.2)(54.2)
Provision for income tax expense23.8 39.5 55.0 74.0 
Interest expense and amortization of debt discounts and fees
60.6 41.8 100.2 84.6 
Depreciation and amortization68.8 63.4 135.0 125.9 
Loss on early extinguishment of debt1.1 1.0 1.4 1.0 
Loss on disposal or impairment of assets2.3 2.9 2.9 2.8 
Stock-based compensation8.8 12.0 16.3 14.8 
Costs associated with the strategic alternatives review22.9 4.1 32.5 5.0 
Costs associated with the Frontier acquisition— 1.3 — 1.3 
Change in fair market value of equity securities3.2 (0.7)5.7 (0.6)
Adjusted EBITDA$240.2 $278.9 $485.2 $529.7 
Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations
Before Income Tax Expense
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
(In Millions)
Total segment Adjusted EBITDA$268.8 $315.7 $545.1 $601.4 
General and administrative expenses(60.3)(54.2)(108.7)(92.8)
Depreciation and amortization(68.8)(63.4)(135.0)(125.9)
Loss on disposal or impairment of assets(2.3)(2.9)(2.9)(2.8)
Loss on early extinguishment of debt(1.1)(1.0)(1.4)(1.0)
Interest expense and amortization of debt discounts and fees
(60.6)(41.8)(100.2)(84.6)
Net income attributable to noncontrolling interests22.6 28.7 45.2 54.2 
Change in fair market value of equity securities(3.2)0.7 (5.7)0.6 
Income from continuing operations before income tax expense
$95.1 $181.8 $236.4 $349.1 

15
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA

Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
(In Millions)
Net cash provided by operating activities
$244.6 $255.9 $463.5 $414.4 
Interest expense and amortization of debt discounts and fees
60.6 41.8 100.2 84.6 
Equity in net income of nonconsolidated affiliates
1.0 1.0 1.9 2.0 
Net income attributable to noncontrolling interests in continuing operations
(22.6)(28.7)(45.2)(54.2)
Amortization of debt-related items
(2.5)(2.0)(4.8)(4.0)
Distributions from nonconsolidated affiliates
(1.9)(0.8)(2.9)(1.8)
Current portion of income tax expense33.7 42.0 62.9 67.8 
Change in assets and liabilities(91.4)(39.3)(116.7)11.0 
Cash (provided by) used in operating activities of discontinued operations(0.1)0.6 — 0.6 
Costs associated with the strategic alternatives review22.9 4.1 32.5 5.0 
Costs associated with the Frontier acquisition— 1.3 — 1.3 
Change in fair market value of equity securities3.2 (0.7)5.7 (0.6)
Other(7.3)3.7 (11.9)3.6 
Adjusted EBITDA$240.2 $278.9 $485.2 $529.7 

16
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
(In Millions)
Net cash provided by operating activities$244.6 $255.9 $463.5 $414.4 
Impact of discontinued operations(0.1)0.6 — 0.6 
Net cash provided by operating activities of continuing operations
244.5 256.5 463.5 415.0 
Capital expenditures for maintenance(39.5)(30.5)(74.0)(53.8)
Distributions paid to noncontrolling interests of consolidated affiliates
(25.3)(24.9)(46.6)(52.7)
Items not indicative of ongoing operating performance:
Transaction costs and related assumed liabilities
26.0 4.5 28.7 4.5 
Adjusted free cash flow$205.7 $205.6 $371.6 $313.0 
For the three months ended June 30, 2022, net cash used in investing activities was $123.2 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended June 30, 2022 was $19.3 million and resulted primarily from cash dividends paid on common stock and distributions to noncontrolling interests of consolidated affiliates.
For the three months ended June 30, 2021, net cash used in investing activities was $226.0 million and primarily resulted from capital expenditures and the acquisition of assets from Frontier Home Health and Hospice. Net cash used in financing activities during the three months ended June 30, 2021 was $186.4 million and primarily resulted from net debt payments, cash dividends paid on common stock, and distributions to noncontrolling interests of consolidated affiliates.
For the six months ended June 30, 2022, net cash used in investing activities was $246.3 million and primarily resulted from capital expenditures. Net cash used in financing activities during the six months ended June 30, 2022 was $80.2 million and primarily resulted from cash dividends paid on common stock and distributions to noncontrolling interests of consolidated affiliates.
For the six months ended June 30, 2021, net cash used in investing activities was $321.6 million and primarily resulted from capital expenditures and the acquisition of assets from Frontier Home Health and Hospice. Net cash used in financing activities during the six months ended June 30, 2021 was $263.9 million and primarily resulted from net debt payments, cash dividends paid on common stock and distributions to noncontrolling interests of consolidated affiliates.
17
Encompass Health Corporation and Subsidiaries
Forward-Looking Statements
Statements contained in this press release and the supplemental information which are not historical facts, such as those relating to the spin off of the home health and hospice business and its impact on the business model, outlook and guidance, the nature of the COVID-19 pandemic and its impact on Encompass Health's business and financial assumptions, legislative and regulatory developments, financial guidance, development projects, balance sheet and cash flow plans, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, Encompass Health, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Encompass Health undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information, involve a number of risks and uncertainties, and relate to, among other things, future events, Encompass Health's plan to repurchase its debt or equity securities, dividend strategies, effective income tax rates, its business strategy, its financial plans, its future financial performance, its projected business results or model, its ability to return value to shareholders, its projected capital expenditures, its leverage ratio, its acquisition opportunities, and the impact of future legislation or regulation. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Encompass Health include, but are not limited to, the continued spread of COVID-19, including the speed, depth, geographic reach and duration of the spread, which could decrease our patient volumes and revenues and lead to staffing and supply shortages and associated cost increases; actions to be taken by the Company in response to the pandemic; the legal, regulatory and administrative developments that occur at the federal, state and local levels; Encompass Health's infectious disease prevention and control efforts; the demand for Encompass Health’s services, including based on any downturns in the economy, consumer confidence, or the capital markets and unemployment among family members; the price of Encompass Health's common stock as it affects Encompass Health's willingness and ability to repurchase shares and the financial and accounting effects of any repurchases; any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings involving Encompass Health, including any matters related to yet undiscovered issues, if any, in acquired operations; Encompass Health's ability to attract and retain key management personnel; any adverse effects on Encompass Health's stock price resulting from the integration of acquired operations; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of Encompass Health's or its vendors' information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information or inability to provide patient care because of system unavailability as well as unforeseen issues, if any, related to integration of acquired systems; the ability to successfully integrate acquired operations, including realization of anticipated tax benefits, revenues, and cost savings, minimizing the negative impact on margins arising from the changes in staffing and other operating practices, and avoidance of unforeseen exposure to liabilities; Encompass Health's ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with its growth strategy; increases in Medicare audit activity, including increased use of sampling and extrapolation, resulting in additional unpaid reimbursement claims and an increase in the backlog of appealed claims denials; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for Encompass Health's services by governmental or private payors; changes in the regulation of the healthcare industry at either or both of the federal and state levels, including as part of national healthcare reform and deficit reduction and Encompass Health's ability to adapt operations to those changes; competitive pressures in the healthcare industry and Encompass Health's response thereto; Encompass Health's ability to obtain and retain favorable arrangements with third-party payors; Encompass Health's ability to control costs, particularly labor and employee benefit costs, including group medical expenses; adverse effects resulting from coverage determinations made by Medicare Administrative Contractors regarding its Medicare reimbursement claims and lengthening delays in Encompass Health's ability to recover improperly denied claims through the administrative appeals process on a timely basis; Encompass Health's ability to adapt to changes in the healthcare delivery system, including value-based purchasing and involvement in coordinated care initiatives or programs that may arise with its referral sources; Encompass Health's ability to attract and
18
Encompass Health Corporation and Subsidiaries
Forward-Looking Statements
retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages, which may be worsened by the pandemic, and the impact on Encompass Health's labor expenses from potential union activity, staffing shortages, and competitive compensation practices; general conditions in the economy and capital markets, including any instability or uncertainty related to armed conflict or an act of terrorism, governmental impasse over approval of the United States federal budget, an increase in the debt ceiling, or an international sovereign debt crisis; the increase in the costs of defending and insuring against alleged professional liability claims, including claims associated with patient and employee exposures to COVID-19, and Encompass Health's ability to predict the estimated costs related to such claims; and other factors which may be identified from time to time in Encompass Health's SEC filings and other public announcements, including Encompass Health's Form 10‑K for the year ended December 31, 2021 and Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022, when filed.
19
Earnings Call April 28, 2022 Supplemental information 2022 First Quarter Second Quarter a l August 2, 2022 Supplemental information

 
Encompass Health 2 The information contained in this presentation includes certain estimates, projections and other forward-looking information that reflect Encompass Health’s current outlook, views and plans with respect to future events, including the effects of the spin off of the home health and hospice business, outlook and guidance, the COVID-19 pandemic and its effects, legislative and regulatory developments, strategy, capital expenditures, acquisition and other development activities, cyber security, dividend strategies, repurchases of securities, effective tax rates, financial performance, financial assumptions, business model, balance sheet and cash flow plans, market share, and shareholder value-enhancing transactions. These estimates, projections and other forward-looking information are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual events or results, and those differences may be material. There can be no assurance any estimates, projections or forward-looking information will be realized. All such estimates, projections and forward-looking information speak only as of the date hereof. Encompass Health undertakes no duty to publicly update or revise the information contained herein. You are cautioned not to place undue reliance on the estimates, projections and other forward-looking information in this presentation as they are based on current expectations and general assumptions and are subject to various risks, uncertainties and other factors, including those set forth in the earnings release attached as Exhibit 99.1 to the Company’s Form 8-K dated August 1, 2022 (the “Q2 Earnings Release Form 8-K”), the Form 10-K for the year ended December 31, 2021, the Form 10-Q for the quarter ended March 31, 2022, the Form 10-Q for the quarter ended June 30, 2022, when filed, and in other documents Encompass Health previously filed with the SEC, many of which are beyond Encompass Health’s control, that may cause actual events or results to differ materially from the views, beliefs and estimates expressed herein. Note regarding presentation of non-GAAP financial measures The following presentation includes certain “non-GAAP financial measures” as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, leverage ratios, adjusted earnings per share, and adjusted free cash flow. Schedules are attached that reconcile the non-GAAP financial measures included in the following presentation to the most directly comparable financial measures calculated and presented in accordance with Generally Accepted Accounting Principles in the United States. The Q2 Earnings Release Form 8-K, to which the following presentation is attached as Exhibit 99.2, provides further explanation and disclosure regarding Encompass Health’s use of non-GAAP financial measures and should be read in conjunction with this supplemental information. Forward-looking statements

 
Encompass Health 3 Q2 2022 Summary ................................................................................................................................................................................. 4 Spin off of Enhabit ................................................................................................................................................................................ 5 Map of locations ..................................................................................................................................................................................... 6 Encompass Health fundamentals ....................................................................................................................................................... 7 Q2 2022 Summary adjusted ............................................................................................................................................................... 8 Key takeaways ....................................................................................................................................................................................... 9-10 Inpatient rehabilitation segment ...................................................................................................................................................... 11-12 Adjusted EBITDA .................................................................................................................................................................................... 13 Earnings per share ................................................................................................................................................................................ 14-15 Adjusted free cash flow ....................................................................................................................................................................... 16 Guidance and considerations for 2022 ............................................................................................................................................ 17-18 Contract labor trends ........................................................................................................................................................................... 19 2022-2026 Growth targets ................................................................................................................................................................. 20 Uses of free cash flow .......................................................................................................................................................................... 21 Adjusted free cash flow assumptions ............................................................................................................................................... 22 Appendix Expansion activity ................................................................................................................................................................................. 24 Pre-payment claims denials - inpatient rehabilitation segment ............................................................................................... 25 Debt maturity profile and schedule ................................................................................................................................................. 26-27 New-store/same-store growth ........................................................................................................................................................... 28 Payment sources (percent of revenues) ......................................................................................................................................... 29 Inpatient rehabilitation operational metrics ................................................................................................................................. 30 Share information ................................................................................................................................................................................. 31 Segment operating results .................................................................................................................................................................. 32-34 Reconciliations to GAAP ...................................................................................................................................................................... 35-42 End notes ................................................................................................................................................................................................ 43-44 Table of contents

 
Encompass Health 4 Q2 2022 Summary Q2 6 Months ($ in millions) 2022 2021 % △ 2022 2021 % △ Encompass Health Consolidated Net operating revenues $ 1,330.5 $ 1,287.7 3.3 % $ 2,664.1 $ 2,518.1 5.8 % Adjusted EBITDA $ 240.2 $ 278.9 (13.9) % $ 485.2 $ 529.7 (8.4) % Adjusted EPS $ 0.89 $ 1.17 (23.9) % $ 1.86 $ 2.22 (16.2) % Adjusted free cash flow $ 205.7 $ 205.6 — % $ 371.6 $ 313.0 18.7 % Inpatient Rehabilitation Segment Net operating revenues $ 1,062.5 $ 1,001.6 6.1 % $ 2,121.8 $ 1,961.5 8.2 % Adjusted EBITDA $ 225.0 $ 254.0 (11.4) % $ 451.2 $ 488.9 (7.7) % Home Health and Hospice Segment Net operating revenues $ 268.0 $ 286.1 (6.3) % $ 542.3 $ 556.6 (2.6) % Adjusted EBITDA $ 43.8 $ 61.7 (29.0) % $ 93.9 $ 112.5 (16.5) % Reconciliations to GAAP provided on pages 35-42

 
Encompass Health 5 Spin off of Enhabit u Spin off of 100% of Enhabit completed on July 1, 2022 Ÿ Enhabit Home Health & Hospice (“Enhabit” or “EHAB”) (NYSE: EHAB) began “regular-way” trading on July 1, 2022. Ÿ Encompass Health stockholders received one share of EHAB for every two shares of EHC stock held as of the close of business June 24, 2022, the record date for the distribution, with cash received in lieu of fractional shares. Ÿ The spin off is expected to be tax free to EHC shareholders, except with respect to cash received in lieu of fractional shares. An IRS Private Letter Ruling has been received. Ÿ Enhabit made a dividend of approximately $567 million to Encompass Health. Encompass Health retired approximately $486 million of existing indebtedness. Ÿ Beginning in Q3 2022, Enhabit will be reported as discontinued operations in Encompass Health’s historical results. Ÿ For information and commentary about Enhabit, including its Q2 2022 results, please refer to Enhabit’s earnings materials filed separately today.

 
Encompass Health 6 ~34,000 employees Rehabilitation hospitals “IRFs” IRFs under development* * IRFs under development - previously announced under development as of August 1, 2022 † Based on 2019 and 2020 data Encompass Health Largest owner and operator of rehabilitation hospitals Company profile as of 07/01/22 150 Rehabilitation hospitals “IRFs” 55 are joint ventures 21 35 IRFs under development* States and Puerto Rico 24% of Licensed beds † 31% of Medicare patients served † Key statistics trailing 4 quarters ~203,600 patient discharges ~$4.2 Billion in revenue

 
Encompass Health 7 Encompass Health fundamentals and value drivers u Large, under penetrated, and growing inpatient rehabilitation market Ÿ Large addressable market indicated by low conversion rate of presumptively eligible inpatient rehabilitation patients Ÿ Favorable demographics driving increased demand for rehabilitation services u Poised to capture incremental market share Ÿ Unparalleled clinical expertise for treating inpatient rehabilitation conditions Ÿ De novo and bed addition strategy delivers attractive financial returns Ÿ Cash flow and capital availability to fund capacity additions Ÿ Significant barriers to entry and economies of scale Ÿ Resilient business model with focus on non-discretionary conditions occurring predominantly in an aging population u Well-positioned to respond to potential changes in IRF patient criteria Ÿ Free-standing inpatient rehabilitation facilities are best able to move up or down the post-acute continuum ü Large clinical workforce of multi-disciplined nurses and therapists ü Physical plant readily adaptable to accommodate historical LTAC and SNF patients u Complementary shareholder distributions Ÿ Cash dividend (currently $0.15 per share per quarter) Ÿ Opportunistic stock repurchases (~$198 million remaining under current authorization)

 
Encompass Health 8 Q2 2022 Summary adjusted - inpatient rehabilitation* Reconciliations to GAAP provided on pages 35-42. * Excludes home health and hospice segment results ** Refer to page 16 for a discussion of year-to-year change. Adjusted Q2* Adjusted 6 months* ($ in millions) 2022 2021 % △ 2022 2021 % △ Encompass Health adjusted* Net operating revenues $ 1,062.5 $ 1,001.6 6.1 % $ 2,121.8 $ 1,961.5 8.2 % Adjusted EBITDA $ 196.4 $ 217.2 (9.6) % $ 391.4 $ 417.2 (6.2) % Adjusted EPS $ 0.62 $ 0.79 (21.5) % $ 1.28 $ 1.52 (15.8) % Adjusted free cash flow** $ 166.8 $ 154.4 8.0 % $ 290.0 $ 239.5 21.1 %

 
Encompass Health 9 Q2 2022 Key takeaways - inpatient rehabilitation* u Revenue growth offset by elevated staffing costs Ÿ Net operating revenue growth of 6.1% Ÿ Strong inpatient rehabilitation discharge growth ü Q2 2022 total discharge growth of 4.9% (1.6% same store) on top of 18.7% (16.9% same store) growth in Q2 2021 Ÿ Staffing costs continue to be elevated, but improved over Q1 2022 ü Q2 2022 contract labor plus sign-on and shift bonuses of $56.9 million vs. $63.0 million in Q1 2022, and $28.7 million in Q2 2021 ü Contract labor FTE’s reduced from peak of 749 in March 2022 to 597 in June 2022 ü See page 19 for more details on contract labor and sign-on and shift bonus trends. u Hiring trends continue to improve Ÿ Same-store net new RN hires of 276 year-to-date through end of Q2 2022 compared to 117 in the first six months of 2021 * Excludes home health and hospice segment results

 
Encompass Health 10 Q2 2022 Key takeaways - inpatient rehabilitation*, cont. u Continued inpatient rehabilitation capacity additions Ÿ Opened 3 de novos in Q2 2022 (140 beds) and added 38 beds to existing hospitals ü YTD added 6 de novos (280 beds) and added 67 beds to existing hospitals Ÿ Plan to open an additional 3 de novos (additional 127 beds) and add an additional 20 beds to existing hospitals in 2022 Ÿ Plan to open 9 de novos and add an additional 100 to 150 beds to existing hospitals in 2023 u Balance sheet - see debt maturity and schedule profile on pages 26-27 Ÿ Paid down approximately $486 million in debt Ÿ Net leverage ratio of 3.3x at quarter end pro forma for spin off of Enhabit u Strong free cash flow generation - see page 16 Ÿ Adjusted free cash flow of $166.8 million; YTD Adjusted free cash flow of $290.0 million u Shareholder distributions Ÿ Paid quarterly cash dividends of $0.28 per share in January, April, and July 2022 Ÿ Declared a $0.15 per share quarterly cash dividend in July 2022 (to be paid in October 2022) ü Dividend revised in response to the recently completed spin off of Enhabit and reflects the Company’s continued commitment to a robust de novo hospital strategy * Excludes home health and hospice segment results

 
Encompass Health 11 Inpatient rehabilitation segment - revenue Q2 Q2 Favorable/ ($ in millions) 2022 2021 (Unfavorable) Net operating revenues: Inpatient $ 1,037.8 $ 976.9 6.2% Outpatient and other 24.7 24.7 —% Total segment revenue $ 1,062.5 $ 1,001.6 6.1% (Actual Amounts) Discharges 51,902 49,492 4.9% Same-store discharge growth 1.6% Net patient revenue per discharge $ 19,995 $ 19,739 1.3% Revenue reserves related to bad debt as a percent of revenue 2.2 % 1.7 % (50) bps u Inpatient revenue growth of 6.2% largely driven by volume gains u Net revenue per discharge growth of 1.3% primarily attributable to an increase in reimbursement rates, partially offset by the resumption of sequestration. u Revenue reserves related to bad debt increased 50 bps to 2.2%, primarily due to the impact of the payor mix shift to Medicare Advantage and Managed Care (longer collection times and higher patient payment responsibility).

 
Encompass Health 12 Inpatient rehabilitation segment - Adjusted EBITDA Q2 % of Revenue Q2 % of Revenue($ in millions) 2022 2021 Net operating revenues $ 1,062.5 $ 1,001.6 Operating expenses: Salaries and benefits (585.9) 55.1 % (515.9) 51.5 % Other operating expenses(a) (166.4) 15.7 % (147.5) 14.7 % Supplies (47.4) 4.5 % (44.1) 4.4 % Occupancy costs (13.8) 1.3 % (15.0) 1.5 % Hospital operating expenses (227.6) 21.4 % (206.6) 20.6 % Other (expense) income(b) (3.1) 2.3 Equity in nonconsolidated affiliates 1.0 0.8 Noncontrolling interests (21.9) (28.2) Segment Adjusted EBITDA $ 225.0 $ 254.0 Percent change (11.4) % In arriving at Adjusted EBITDA, the following were excluded: (a) Loss on disposal or impairment of assets $ 2.7 $ 3.3 (b) Change in fair market value of equity securities $ 3.2 $ (0.7) Reconciliations to GAAP provided on pages 35-42. u Salary and benefits in Q2 2022 included $56.9 million in agency staffing and sign-on and shift bonuses, compared to $28.7 million in Q2 2021. u Other operating expenses included increases of $4.4 million in recruiting expense and $2.8 million in provider tax expense. u Other (expense) income included a $4.0 million unfavorable mark-to-market adjustment on non-qualified 401k plan compared to a $1.8 million favorable adjustment in Q2 2021. These expenses are offset entirely within G&A.

 
Encompass Health 13 Adjusted EBITDA - inpatient rehabilitation* ($ in millions) Q2 2022 % of Consolidated Revenue Q2 2021 % of Consolidated Revenue Inpatient rehabilitation segment Adjusted EBITDA $ 225.0 $ 254.0 General and administrative expenses** (28.6) 2.1% (36.8) 2.9% Encompass Health Adjusted EBITDA* $ 196.4 $ 217.2 Percentage change (9.6) % Reconciliations to GAAP provided on pages 35-42. u General and administrative expenses decreased as a percent of consolidated revenue due to improved operating leverage, a decline in the mark-to-market value of the Company’s non-qualified 401(k) plan, and lower incentive compensation in Q2 2022. ** General and administrative expenses in the above table exclude stock compensation of $8.8 million and $12.0 million for Q2 2022 and Q2 2021, respectively, as well as $22.9 million and $4.1 million in costs associated with the strategic alternatives review of our home health and hospice business for Q2 2022 and Q2 2021, respectively. * Excludes home health and hospice segment

 
Encompass Health 14 Earnings per share - as reported Q2 6 Months ($ in millions, except per share data) 2022 2021 2022 2021 Adjusted EBITDA $ 240.2 $ 278.9 $ 485.2 $ 529.7 Depreciation and amortization (68.8) (63.4) (135.0) (125.9) Interest expense and amortization of debt discounts and fees (60.6) (41.8) (100.2) (84.6) Stock-based compensation (8.8) (12.0) (16.3) (14.8) Loss on disposal or impairment of assets (2.3) (2.9) (2.9) (2.8) 99.7 158.8 230.8 301.6 Items not indicative of ongoing operating performance: Loss on early extinguishment of debt(1)(2)(3) (1.1) (1.0) (1.4) (1.0) Costs associated with the strategic alternatives review (22.9) (4.1) (32.5) (5.0) Costs associated with the Frontier acquisition — (1.3) — (1.3) Change in fair market value of equity securities (3.2) 0.7 (5.7) 0.6 Pre-tax income 72.5 153.1 191.2 294.9 Income tax expense (23.8) (39.5) (55.0) (74.0) Income from continuing operations* $ 48.7 $ 113.6 $ 136.2 $ 220.9 Diluted shares (see page 31) 100.3 100.2 100.2 100.2 Diluted earnings per share* $ 0.49 $ 1.13 $ 1.36 $ 2.20 u EPS in Q2 2022 was impacted by higher contract labor costs resulting in lower Adjusted EBITDA, higher interest expense and amortization of debt discounts and fees, and higher costs associated with the strategic alternatives review. * Earnings per share are determined using income from continuing operations attributable to Encompass Health. Refer to pages 43-44 for end notes.

 
Encompass Health 15 Adjusted earnings per share(4) Refer to pages 43-44 for end notes. Q2 6 Months 2022 2021 2022 2021 Earnings per share, as reported $ 0.49 $ 1.13 $ 1.36 $ 2.20 Adjustments, net of tax: Costs associated with the strategic alternatives review 0.32 0.03 0.39 0.04 Costs associated with the Frontier acquisition — 0.01 — 0.01 Income tax adjustments 0.05 — 0.06 (0.03) Loss on early extinguishment of debt(1)(2)(3) 0.01 0.01 0.01 0.01 Change in fair market value of equity securities 0.02 — 0.04 — Adjusted earnings per share* $ 0.89 $ 1.17 $ 1.86 $ 2.22 Adjusted earnings per share Encompass Health adjusted** $ 0.62 $ 0.79 $ 1.28 $ 1.52 u Adjusted earnings per share removes from the GAAP earnings per share calculation the impact of items the Company believes are non-indicative of its ongoing operating performance. * Adjusted EPS may not sum due to rounding. See complete calculations of adjusted earnings per share on pages 39-42. ** Excludes home health and hospice segment results

 
Encompass Health 16 239.5 (25.8) 44.1 5.7 47.3 (20.8) 290.0 Adjusted Free Cash Flow 6 Mos. 2021 Adjusted EBITDA Working capital and other Cash interest payments Cash tax payments, net of refunds Maintenance capital expenditures Adjusted Free Cash Flow 6 Mos. 2022 2022 YTD Adjusted free cash flow(5)- inpatient rehabilitation* Reconciliations to GAAP provided on pages 35-42. Refer to pages 43-44 for end notes. u Adjusted free cash flow growth in the first six months of 2022 was predominantly attributable to improved working capital. Ÿ Accounts receivable in the first six months of 2021 was elevated due to IRF Medicare payment processing delays. ($ in millions) * Excludes home health and hospice segment results

 
Encompass Health 17 2022 Guidance for Encompass Health - inpatient rehabilitation* 2021 Adjusted* Affirmed 2022 Guidance** ($ in millions, except per share data) Net Operating Revenue $4,015 $4,250 to $4,300 Adjusted EBITDA(6) $817 $820 to $840 Adjusted earnings per share from continuing operations attributable to Encompass(4) $2.93 $2.77 to $2.91 * Excludes home health and hospice segment results ** Excludes nonrecurring costs related to the separation of Enhabit Refer to pages 43-44 for end notes.

 
Encompass Health 18 2022 Guidance considerations for Encompass Health u Encompass Health will operate a single reportable segment: inpatient rehabilitation Ÿ A net increase of approximately 1.9% in Medicare pricing for Q3 and 4.0% for Q4, prior to the resumption of sequestration* Ÿ Revenue reserves related to bad debt of approximately 2.0% to 2.2% of net operating revenues** ü Reflects continued payor mix shift to Medicare Advantage and Managed Care ü Medicare contractors’ recent resumption of Targeted Probe and Educate adds to uncertainty (see page 25) Ÿ Salaries and benefits per FTE (inclusive of agency staffing costs, sign-on and shift bonuses) is expected to increase by approximately 5%. Staffing constraints and elevated costs are expected to continue in 2022 with improvement heavily skewed toward the second half of the year. ü 1H 2022 salaries and benefits per FTE increase was approximately 8% ü 2H 2022 salaries and benefits per FTE increase expected to be approximately 2% Ÿ Employees per occupied bed expected to be approximately 3.38 to 3.42 for the remainder of 2022 ü Impact of new hospitals opening in 2022 ü Normalization of staffing ratios as constraints subside Ÿ Net pre-opening and new-store ramp-up costs incurred in 1H 2022 of $15 million ü Licensing and certification delays in certain markets impacted opening dates ü New-store positive contributions in 2H will contribute up to $3 million net offset to 1H net pre- opening and new-store ramp-up costs (2022 full year range of $12 to $15 million)*** Ÿ Anticipate receipt of $1 to $3 million associated with the transition services agreement with Enhabit (an offset to general and administrative costs) Ÿ Tax rate of approximately 26% Ÿ Diluted share count of approximately 100 million shares Ÿ Guidance excludes nonrecurring costs related to the separation of Enhabit. * Previously estimated as 1.9% for all of 2022 ** Previously estimated as 2.0% *** Previously estimated as $10 to $13 million

 
Encompass Health 19 Contract labor and sign-on and shift bonus trends* 2020 2021 2022 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Contract labor and sign-on and shift bonus expense trends ($ in millions) Sign-on/shift bonus $ 5.1 $ 4.5 $ 6.9 $ 9.1 $ 10.8 $ 12.7 $ 15.0 $ 21.3 $ 21.1 $ 21.8 Contract labor $ 6.1 $ 4.5 $ 6.5 $ 7.5 $ 10.1 $ 16.0 $ 18.3 $ 30.0 $ 41.9 $ 35.1 Total $ 11.2 $ 9.0 $ 13.4 $ 16.6 $ 20.9 $ 28.7 $ 33.3 $ 51.3 $ 63.0 $ 56.9 Contract labor FTE trends ($ in thousands) Contract FTEs 161 116 176 192 221 318 383 516 706 633 Agency rate/FTE $ 151.4 $ 155.6 $ 147.5 $ 155.9 $ 185.2 $ 201.3 $ 189.5 $ 230.7 $ 240.4 $ 222.6 u Sign-on and shift bonuses remained elevated in Q2 2022, as hiring increased (127 net RN hires in Q1 and 149 in Q2) and we used internal staffing (shift bonuses) when possible. u Contract labor expense declined sequentially in Q2 2022. Ÿ We expect contract labor expense to continue to decline sequentially in Q3 and Q4 2022. u Contract labor FTEs peaked in March 2022 at 749; and declined to 597 in June 2022. u Contract labor agency rate / FTE declined sequentially (Q2’22 vs. Q1’22) but remains highly variable. Ÿ We expect 2H 2022 rates to be lower than the average of 1H 2022 rates, however the recent PHE extension may prolong elevated contract labor rates. * Excludes home health and hospice segment results

 
Encompass Health 20 2022-2026 Growth targets for Encompass Health Strong and sustainable business fundamentals Ÿ Strong demographic tailwinds Ÿ Multi-faceted growth strategy Ÿ Highly fragmented sector presents unit acquisition and joint venture opportunities Ÿ Consistent delivery of high-quality, cost-effective care Ÿ Economies related to scale and market density Ÿ Substantial cash flow generation 6 to 10 de novos per year 100 to 150 bed additions per year 6% to 8% discharge CAGR

 
Encompass Health 21 Uses of free cash flow for Encompass Health ($ in millions) 2021 Adjusted* 2022 Assumptions Growth in core business IRF bed expansions $48.6 $40 to $50 New IRFs - De novos 314.9 320 to 340 - Acquisitions 1.1 opportunistic - Replacement IRFs and other 48.9 10 to 20 $413.5 $370 to $410 Debt reduction Debt redemptions (borrowings), net $1.0 TBD Shareholder distributions Cash dividends on common stock 112.4 TBD Common stock repurchases — opportunistic Ÿ ~$198 million remaining under current authorization as of June 30, 2022(7) Refer to pages 43-44 for end notes. * Excludes home health and hospice segment results

 
Encompass Health 22 Adjusted free cash flow(5) assumptions for Encompass Health Certain cash flow items ($ in millions) 2021 Adjusted* 2022 Assumptions Cash interest payments (net of amortization of debt discounts and fees) $156.6 $140 to $150 Cash payments for income taxes, net of refunds $101.2 $70 to $80 Working capital and other $71.1 $50 to $70 Maintenance CAPEX $133.4 $200 to $240 Adjusted free cash flow $354.2 $280 to $380 Decrease due to overpayments from 2021 applied to 2022 Decrease in working capital expected due to timing of collections Increased maintenance CAPEX related to carryover projects from 2021 (due to supply chain challenges), additional spending for equipment replacement, and renovations to existing hospitals Cash interest payments expected to decrease due to debt repayment with distribution proceeds from Enhabit * Excludes home health and hospice segment results Refer to pages 43-44 for end notes.

 
Appendix

 
Encompass Health 24 Inpatient Rehabilitation Facilities Opened or Under Development Expected operations date Joint venture # of New Beds 2022 2023 2024 2025 De novo IRFs: Shiloh, IL Q1 2022 ü 40 — — — St. Augustine, FL Q1 2022 40 — — — Libertyville, IL Q1 2022 60 — — — Lakeland, FL Q2 2022 50 — — — Cape Coral, FL Q2 2022 ü 40 — — — Jacksonville, FL Q2 2022 50 — — — 1 Moline, IL Q3 2022 ü 40 — — — 2 Naples, FL Q3 2022 ü 50 — — — 3 Grand Forks, ND Q3 2022 ü 37 — — — 4 Eau Claire, WI 2023 ü — 36 — — 5 Owasso, OK 2023 ü — 40 — — 6 Clermont, FL 2023 — 50 — — 7 Knoxville, TN 2023 ü — 73 — — 8 Bowie, MD 2023 — 60 — — 9 Prosper, TX 2023 — 40 — — 10 Columbus, GA 2023 ü — 40 — — 11 Fitchburg, WI 2023 — 40 — — 12 Louisville, KY 2023 ü — 40 — — 13 Kissimmee, FL TBD — — 50 — 14 Fort Mill, SC TBD — — 39 — 15 Atlanta, GA TBD ü — — 40 — 16 Fort Myers, FL TBD ü — — 60 — 17 Houston, TX TBD — — 60 — 18 Lake Worth, FL TBD — — — 50 19 Palm Beach Gardens, FL TBD — — — 50 20 Amarillo, TX TBD — — — 40 21 Strongsville, OH TBD — — — 40 Bed expansions, net* ~90 ~100 ~100 ~100 ~500 ~520 ~350 ~280 Expansion activity *Net bed expansions in each year may change due to the timing of certain regulatory approvals and/or construction delays. For 2022 through 2025, the currently expected range for bed expansions is 100 to 150. Q2 2022 Expansion activity highlights u Opened 3 inpatient rehabilitation hospitals Ÿ 50-bed IRF in Lakeland, FL Ÿ 40-bed IRF in Cape Coral, FL Ÿ 50-bed IRF in Jacksonville, FL u Added 38 beds to existing hospitals u Announced plans to build a 40-bed satellite inpatient rehabilitation hospital in Town and Country, MO IRF development projects announced and underway 21 The 150th hospital Jacksonville, FL

 
Encompass Health 25 Pre-payment claims denials - inpatient rehabilitation segment Impact to Income Statement Period New Denials Collections of Previously Denied Claims Revenue Reserve for New Denials Update of Reserve for Prior Denials ($ in millions) Q2 2022 $12.5 $(6.5) $1.4 $— Q1 2022 1.1 (5.6) 0.3 — Q4 2021 1.4 (8.1) 0.4 — Q3 2021 (0.5) (9.7) — — Q2 2021 0.1 (6.3) — — Q1 2021 (0.2) (5.2) — — Q4 2020 (0.4) (7.2) — 4.5 Q3 2020 (0.6) (6.3) — — Q2 2020 (1.5) (3.5) — — Q1 2020 4.2 (5.0) 1.3 — Q4 2019 3.8 (4.6) 1.1 — Q3 2019 11.3 (6.1) 3.4 — Impact to Balance Sheet June 30, 2022 Dec. 31, 2021 Dec. 31, 2020 ($ in millions) Pre-payment claims denials $ 57.0 $ 69.0 $ 122.8 Recorded reserves (17.1) (25.7) (41.3) Net accounts receivable from pre-payment claim denials $ 39.9 $ 43.3 $ 81.5 * For more information regarding TPE, see https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/ Medicare-FFS-Compliance-Programs/Medical-Review/Targeted-Probe-and-EducateTPE.html u Encompass Health reserves pre-payment claim denials as a reduction of net operating revenues upon notice that a claim is under review. u Encompass Health appealed thousands of claims CMS contractors denied under “widespread probe” programs prior to 2018. These appeals went to Administrative Law Judges (“ALJs”) at HHS, and became part of a nationwide backlog of cases at the ALJ level that a federal judge ordered HHS to clear by the end of 2022. u Encompass Health has approximately 140 claims pending at the ALJ level that have not been heard to date. Encompass Health has another 118 claims that have been heard by an ALJ but have not been decided. u Encompass Health has appealed another 2,444 claims that were denied at the ALJ level to the HHS Departmental Appeals Board (“DAB”), the highest level of administrative review. We do not know how long it will take the DAB to rule on these appeals. u As of June 30, 2022, approximately $30 million of net accounts receivable from pre-payment claims denials relate to the above outstanding claims. u CMS started the Targeted Probe and Educate (“TPE”) initiative in August 2017 but suspended TPE reviews in March 2020. CMS resumed the TPE program in September 2021. The Medicare contractors started IRF specific TPE reviews in 2022 resulting in an increase in new denials and associated reserves. We expect elevated claim review activity and higher reserves in 2H 2022.

 
Encompass Health 26 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 * This chart does not include ~$371 of finance lease obligations or ~$42 of other notes payable See the debt schedule on page 27 Debt maturity profile - face value $350 Senior Notes 5.75% ($ in millions) Revolver capacity $800 Senior Notes 4.75% $800 Senior Notes 4.5% Revolver Profile as of July 1, 2022* $967 Available $— Drawn + $33 reserved for LCs Callable Callable beginning February 2025Callable beginning February 2023 $400 Senior Notes 4.625% Callable beginning April 2026

 
Encompass Health 27 Debt schedule Pro forma Change in June 30, June 30, December 31, Debt vs. ($ in millions) 2022* 2022 2021 YE 2021 EHC Credit Agreement— Advances under $1 billion revolving credit facility, November 2024 - LIBOR +150bps(1) $ — $ — $ 200.0 $ (200.0) Term loan facility, November 2024 - LIBOR +150bps(1) — — 238.5 (238.5) EHAB Credit Agreement— Advances under $350 million revolving credit facility, June 2027 - SOFR + 175 bps n/a 170.0 — 170.0 Term loan facility, June 2027 - SOFR +175 bps n/a 397.7 — 397.7 Bonds Payable: 5.125% Senior Notes due 2023(2)(3) — — 99.6 (99.6) 5.75% Senior Notes due 2025 347.4 347.4 347.0 0.4 4.50% Senior Notes due 2028 780.2 780.2 786.8 (6.6) 4.75% Senior Notes due 2030 777.8 777.8 784.7 (6.9) 4.625% Senior Notes due 2031 390.1 390.1 393.7 (3.6) Other notes payable 42.3 42.3 49.6 (7.3) Finance lease obligations 371.0 377.2 386.8 (9.6) Long-term debt $ 2,708.8 $ 3,282.7 $ 3,286.7 $ (4.0) Debt to Adjusted EBITDA 3.4 x 3.3 x 3.2 x Leverage net of cash on balance sheet 3.3 x 3.1 x 3.1 x Reconciliations to GAAP provided on pages 35-42. Refer to pages 43-44 for end notes. *Adjusted to reflect Encompass Health on a stand alone basis for the spin off of Enhabit completed July 1, 2022.

 
Encompass Health 28 -10.0% 0.0% 10.0% 20.0% * Includes consolidated inpatient rehabilitation hospitals classified as same store during each period Refer to pages 43-44 for end notes. New-store/same-store growth Inpatient Rehabilitation Yuma, AZ (51 beds)(8) Boise, ID (40 beds) Katy, TX (40 beds) North Tampa, FL (50 beds) Cumming, GA (50 beds) Shreveport, LA (40 beds) Waco, TX (40 beds) Greenville, SC (40 beds) Pensacola, FL (40 beds) Discharges Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 New store 2.4% 2.0% 2.3% 2.1% 1.3% 0.9% 1.0% 1.8% 2.0% 3.6% 3.8% 3.3% Same store* 3.1% 3.2% 2.4% (12.8)% (2.8)% (3.8)% (2.2)% 16.9% 6.7% 6.0% 3.8% 1.6% Total by quarter 5.5% 5.2% 4.7% (10.7)% (1.5)% (2.9)% (1.2)% 18.7% 8.7% 9.6% 7.6% 4.9% Total by year 3.9% (2.6)% 8.7% Same-store year* 1.8% (4.4)% 6.2% Same-store year UDS(9) 1.3% (3.2)% 2.3% Murrieta, CA (50 beds) Sioux Falls, SD (40 beds) Coralville, IA (40 beds) Beginning in mid-March 2020, volume growth was impacted by COVID-19. Toledo, OH (40 beds) San Angelo, TX (40 beds) Shiloh, IL (40 beds) St. Augustine, FL (40 beds) Libertyville, IL (60 beds) Henry County, GA (50 beds) Lakeland, FL (50 beds) Cape Coral, FL (40 beds) Jacksonville, FL (50 beds)

 
Encompass Health 29 Payment sources (percent of revenues)* Inpatient Rehabilitation Q2 6 Months Full Year 2022 2021 2022 2021 2021 Medicare 64.9 % 65.0 % 65.1 % 64.4 % 64.4 % Medicare Advantage 15.1 % 15.3 % 14.9 % 15.9 % 15.2 % Managed care 11.6 % 11.5 % 12.0 % 11.6 % 12.1 % Medicaid 4.5 % 4.2 % 4.2 % 4.1 % 4.1 % Other third-party payors 0.9 % 1.1 % 0.9 % 1.2 % 1.1 % Workers’ compensation 0.6 % 0.5 % 0.6 % 0.6 % 0.6 % Patients 0.4 % 0.4 % 0.4 % 0.5 % 0.5 % Other income 2.0 % 2.0 % 1.9 % 1.7 % 2.0 % Total 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % * Excludes home health and hospice segment results

 
Encompass Health 30 Inpatient rehabilitation operational metrics Q2 Q1 Q4 Q3 Q2 Q1 Full Year 2022 2022 2021 2021 2021 2021 2021 Net patient revenue-inpatient $ 1,037.8 $ 1,036.2 $ 1,015.2 $ 983.7 $ 976.9 $ 942.3 $ 3,918.1 Net patient revenue-outpatient and other revenues 24.7 23.1 27.4 27.2 24.7 17.6 96.9 Net operating revenues $ 1,062.5 $ 1,059.3 $ 1,042.6 $ 1,010.9 $ 1,001.6 $ 959.9 $ 4,015.0 Discharges(10) 51,902 50,771 50,977 49,983 49,492 47,187 197,639 Net patient revenue per discharge $ 19,995 $ 20,409 $ 19,915 $ 19,681 $ 19,739 $ 19,969 $ 19,825 Outpatient visits 35,929 35,229 37,952 38,904 44,020 40,194 161,070 Average length of stay 12.6 13.0 12.8 12.8 12.7 13.0 12.8 Occupancy % 70.7 % 73.1 % 71.5 % 70.6 % 71.1 % 71.4 % 70.0 % # of licensed beds 10,206 10,028 9,924 9,846 9,701 9,560 9,924 Occupied beds 7,216 7,330 7,096 6,951 6,897 6,826 6,947 Full-time equivalents (FTEs)(11) 23,649 23,313 23,364 23,054 22,535 22,383 22,834 Contract labor 633 706 516 383 318 221 359 Total FTE and contract labor 24,282 24,019 23,880 23,437 22,853 22,604 23,193 EPOB(12) 3.37 3.28 3.37 3.37 3.31 3.31 3.34 Refer to pages 43-44 for end notes.

 
Encompass Health 31 Share information Weighted Average for the Period Q2 6 Months Full Year (in millions) 2022 2021 2022 2021 2021 2020 2019 Basic shares outstanding 99.2 99.0 99.2 99.0 99.0 98.6 98.0 Restricted stock awards, dilutive stock options, restricted stock units, and common stock warrants 1.1 1.2 1.0 1.2 1.2 1.2 1.4 Diluted shares outstanding 100.3 100.2 100.2 100.2 100.2 99.8 99.4 End of Period Q2 6 Months Full Year (in millions) 2022 2021 2022 2021 2021 2020 2019 Basic shares outstanding 99.8 99.5 99.8 99.5 99.5 99.4 98.6

 
Encompass Health 32 Segment operating results Q2 2022 Q2 2021 ($ in millions) IRF Home Health and Hospice Reclasses Consolidated IRF Home Health and Hospice Reclasses Consolidated Net operating revenues $ 1,062.5 $ 268.0 $ — $ 1,330.5 $ 1,001.6 $ 286.1 $ — $ 1,287.7 Operating Expenses: Inpatient Rehabilitation: Salaries and benefits (585.9) — (187.9) (773.8) (515.9) — (192.3) (708.2) Other operating expenses(a) (166.4) — (24.7) (191.1) (147.5) — (22.3) (169.8) Supplies (47.4) — (5.4) (52.8) (44.1) — (5.9) (50.0) Occupancy costs (13.8) — (5.5) (19.3) (15.0) — (5.2) (20.2) Home Health and Hospice: Cost of services (excluding depreciation and amortization) — (124.2) 124.2 — — (122.6) 122.6 — Support and overhead costs — (99.3) 99.3 — — (103.1) 103.1 — (813.5) (223.5) — (1,037.0) (722.5) (225.7) — (948.2) Other (expense) income(b) (3.1) — — (3.1) 2.3 1.6 — 3.9 Equity in net income of nonconsolidated affiliates 1.0 — — 1.0 0.8 0.2 — 1.0 Noncontrolling interests (21.9) (0.7) — (22.6) (28.2) (0.5) — (28.7) Segment Adjusted EBITDA $ 225.0 $ 43.8 $ — 268.8 $ 254.0 $ 61.7 $ — 315.7 General and administrative expenses(c)(d)(e) (28.6) (36.8) Adjusted EBITDA $ 240.2 $ 278.9 In arriving at Adjusted EBITDA, the following were excluded: (a) Loss (gain) on disposal or impairment of assets $ 2.7 $ (0.4) $ — $ 2.3 $ 3.3 $ (0.4) $ — $ 2.9 (b) Change in fair market value of equity securities $ 3.2 $ — $ — $ 3.2 $ (0.7) $ — $ — $ (0.7) (c) Stock-based compensation $ — $ — $ — $ 8.8 $ — $ — $ — $ 12.0 (d) Costs associated with the strategic alternatives review $ — $ — $ — $ 22.9 $ — $ — $ — $ 4.1 (e) Costs associated with the Frontier acquisition $ — $ — $ — $ — $ — $ — $ — $ 1.3 Reconciliations to GAAP provided on pages 35-42.

 
Encompass Health 33 Segment operating results Six Months Ended June 30, 2022 Six Months Ended June 30, 2021 ($ in millions) IRF Home Health and Hospice Reclasses Consolidated IRF Home Health and Hospice Reclasses Consolidated Net operating revenues $ 2,121.8 $ 542.3 $ — $ 2,664.1 $ 1,961.5 $ 556.6 $ — $ 2,518.1 Operating Expenses: Inpatient Rehabilitation: Salaries and benefits (1,173.3) — (376.5) (1,549.8) (1,017.8) — (377.6) (1,395.4) Other operating expenses(a) (324.7) — (47.9) (372.6) (287.5) — (44.7) (332.2) Supplies (97.2) — (11.7) (108.9) (89.3) — (12.6) (101.9) Occupancy costs (29.2) — (11.0) (40.2) (30.1) — (10.3) (40.4) Home Health and Hospice: Cost of services (excluding depreciation and amortization) — (248.6) 248.6 — — (240.7) 240.7 — Support and overhead costs — (198.5) 198.5 — — (204.5) 204.5 — (1,624.4) (447.1) — (2,071.5) (1,424.7) (445.2) — (1,869.9) Other (expense) income(b) (4.2) — — (4.2) 3.8 1.6 — 5.4 Equity in net income of nonconsolidated affiliates 1.9 — — 1.9 1.6 0.4 — 2.0 Noncontrolling interests (43.9) (1.3) — (45.2) (53.3) (0.9) — (54.2) Segment Adjusted EBITDA $ 451.2 $ 93.9 $ — 545.1 $ 488.9 $ 112.5 $ — 601.4 General and administrative expenses(c)(d)(e) (59.9) (71.7) Adjusted EBITDA $ 485.2 $ 529.7 In arriving at Adjusted EBITDA, the following were excluded: (a) Loss (gain) on disposal or impairment of assets $ 3.4 $ (0.5) $ — $ 2.9 $ 3.3 $ (0.5) $ — $ 2.8 (b) Change in fair market value of equity securities $ 5.7 $ — $ — $ 5.7 $ (0.6) $ — $ — $ (0.6) (c) Stock-based compensation $ — $ — $ — $ 16.3 $ — $ — $ — $ 14.8 (d) Costs associated with the strategic alternatives review $ — $ — $ — $ 32.5 $ — $ — $ — $ 5.0 (e) Costs associated with the Frontier acquisition $ — $ — $ — $ — $ — $ — $ — $ 1.3 Reconciliations to GAAP provided on pages 35-42

 
Encompass Health 34 Segment operating results Year Ended December 31, 2021 ($ in millions) IRF Home Health and Hospice Reclasses Consolidated Net operating revenues $ 4,015.0 $ 1,106.6 $ — $ 5,121.6 Operating Expenses: Inpatient Rehabilitation: Salaries and benefits (2,127.3) — (759.2) (2,886.5) Other operating expenses(a) (594.8) — (90.0) (684.8) Supplies (184.2) — (25.1) (209.3) Occupancy costs (59.0) — (21.2) (80.2) Home Health and Hospice: Cost of services (excluding depreciation and amortization) — (489.3) 489.3 — Support and overhead costs — (406.2) 406.2 — (2,965.3) (895.5) — (3,860.8) Other income(b)(c) 6.9 1.6 — 8.5 Equity in net income of nonconsolidated affiliates 3.4 0.6 — 4.0 Noncontrolling interests (103.2) (1.8) — (105.0) Segment Adjusted EBITDA $ 956.8 $ 211.5 $ — 1,168.3 General and administrative expenses(d)(e)(f) (140.3) Adjusted EBITDA $ 1,028.0 In arriving at Adjusted EBITDA, the following were excluded: (a) Loss (gain) on disposal or impairment of assets $ 1.2 $ (0.8) $ — $ 0.4 (b) Change in fair market value of equity securities $ (0.6) $ — $ — $ (0.6) (c) Gain on consolidation of former equity method location(13) $ — $ (3.2) $ — $ (3.2) (d) Stock-based compensation $ — $ — $ — $ 32.8 (e) Costs associated with the strategic alternatives review $ — $ — $ — $ 22.9 (f) Costs associated with the Frontier acquisition $ — $ — $ — $ 1.3 Reconciliations to GAAP provided on pages 35-42. Refer to pages 43-44 for end notes.

 
Encompass Health 35 Reconciliation of net income to Adjusted EBITDA(6) Three Months Ended June 30, Six Months Ended June 30, Year Ended 2022 2021 2022 2021 2021 (In Millions) Net income $ 71.3 $ 142.0 $ 181.4 $ 274.8 $ 517.2 Loss from discontinued operations, net of tax, attributable to Encompass Health — 0.3 — 0.3 0.4 Net income attributable to noncontrolling interests (22.6) (28.7) (45.2) (54.2) (105.0) Income from continuing operations attributable to Encompass Health 48.7 113.6 136.2 220.9 412.6 Provision for income tax expense 23.8 39.5 55.0 74.0 139.6 Interest expense and amortization of debt discounts and fees 60.6 41.8 100.2 84.6 164.6 Depreciation and amortization 68.8 63.4 135.0 125.9 256.6 Loss on early extinguishment of debt (1)(2)(3) 1.1 1.0 1.4 1.0 1.0 Loss on disposal or impairment of assets 2.3 2.9 2.9 2.8 0.4 Stock-based compensation 8.8 12.0 16.3 14.8 32.8 Costs associated with the strategic alternatives review 22.9 4.1 32.5 5.0 22.9 Costs associated with the Frontier acquisition — 1.3 — 1.3 1.3 Gain on consolidation of former equity method location (13) — — — — (3.2) Change in fair market value of equity securities 3.2 (0.7) 5.7 (0.6) (0.6) Consolidated Adjusted EBITDA 240.2 278.9 485.2 529.7 1,028.0 Remove Home Health and Hospice segment Adjusted EBITDA (43.8) (61.7) (93.8) (112.5) (211.5) Adjusted EBITDA — Encompass Health adjusted $ 196.4 $ 217.2 $ 391.4 $ 417.2 $ 816.5 Refer to pages 43-44 for end notes.

 
Encompass Health 36 Net cash provided by operating activities reconciled to Adjusted EBITDA(6) Q2 6 Months Full Year ($ in millions) 2022 2021 2022 2021 2021 Net cash provided by operating activities $ 244.6 $ 255.9 $ 463.5 $ 414.4 $ 715.8 Interest expense and amortization of debt discounts and fees 60.6 41.8 100.2 84.6 164.6 Equity in net income of nonconsolidated affiliates 1.0 1.0 1.9 2.0 4.0 Net income attributable to noncontrolling interests in continuing operations (22.6) (28.7) (45.2) (54.2) (105.0) Amortization of debt-related items (2.5) (2.0) (4.8) (4.0) (7.8) Distributions from nonconsolidated affiliates (1.9) (0.8) (2.9) (1.8) (2.9) Current portion of income tax expense 33.7 42.0 62.9 67.8 111.8 Change in assets and liabilities (91.4) (39.3) (116.7) 11.0 118.0 Cash (provided by) used in operating activities of discontinued operations (0.1) 0.6 — 0.6 0.5 Costs associated with the strategic alternatives review 22.9 4.1 32.5 5.0 22.9 Costs associated with the Frontier acquisition — 1.3 — 1.3 1.3 Change in fair market value of equity securities 3.2 (0.7) 5.7 (0.6) (0.6) Other (7.3) 3.7 (11.9) 3.6 5.4 Consolidated Adjusted EBITDA $ 240.2 $ 278.9 $ 485.2 $ 529.7 $ 1,028.0 Remove Home Health and Hospice segment Adjusted EBITDA (43.8) (61.7) (93.8) (112.5) (211.5) Adjusted EBITDA — Encompass Health adjusted $ 196.4 $ 217.2 $ 391.4 $ 417.2 $ 816.5 Refer to pages 43-44 for end notes.

 
Encompass Health 37 Reconciliation of segment Adjusted EBITDA to income from continuing operations before income tax expense Three Months Ended Six Months Ended Year Ended June 30, June 30, December 31, 2022 2021 2022 2021 2021 ($ in millions) Total segment Adjusted EBITDA $ 268.8 $ 315.7 $ 545.1 $ 601.4 $ 1,168.3 General and administrative expenses (60.3) (54.2) (108.7) (92.8) (197.3) Depreciation and amortization (68.8) (63.4) (135.0) (125.9) (256.6) Loss on disposal or impairment of assets (2.3) (2.9) (2.9) (2.8) (0.4) Loss on early extinguishment of debt(1)(2)(3) (1.1) (1.0) (1.4) (1.0) (1.0) Interest expense and amortization of debt discounts and fees (60.6) (41.8) (100.2) (84.6) (164.6) Net income attributable to noncontrolling interests 22.6 28.7 45.2 54.2 105.0 Change in fair market value of equity securities (3.2) 0.7 (5.7) 0.6 0.6 Gain on consolidation of former equity method location(13) — — — — 3.2 Income from continuing operations before income tax expense $ 95.1 $ 181.8 $ 236.4 $ 349.1 $ 657.2 Refer to pages 43-44 for end notes.

 
Encompass Health 38 Reconciliation of net cash provided by operating activities to adjusted free cash flow(5) Q2 6 Months Full Year ($ in millions) 2022 2021 2022 2021 2021 Net cash provided by operating activities $ 244.6 $ 255.9 $ 463.5 $ 414.4 $ 715.8 Impact of discontinued operations (0.1) 0.6 — 0.6 0.5 Net cash provided by operating activities of continuing operations 244.5 256.5 463.5 415.0 716.3 Capital expenditures for maintenance (39.5) (30.5) (74.0) (53.8) (138.8) Distributions paid to noncontrolling interests of consolidated affiliates (25.3) (24.9) (46.6) (52.7) (102.9) Items not indicative of ongoing operating performance: Transaction costs and related assumed liabilities 26.0 4.5 28.7 4.5 24.2 Consolidated Adjusted free cash flow $ 205.7 $ 205.6 $ 371.6 $ 313.0 $ 498.8 Remove Home Health and Hospice segment results (38.9) (51.2) (81.6) (73.5) (144.6) Adjusted free cash flow — Encompass Health adjusted $ 166.8 $ 154.4 $ 290.0 $ 239.5 $ 354.2 Cash dividends on common stock $ 27.8 $ 27.8 $ 56.3 $ 56.9 $ 112.4 Refer to pages 43-44 for end notes.

 
Encompass Health 39 Adjusted EPS(4) - Q2 2022 For the Three Months Ended June 30, 2022 Adjustments As Reported Loss on Early Exting. of Debt Income Tax Adjustments Costs Associated with the Strategic Alternatives Review Change in Fair Market Value of Equity Securities Consolidated As Adjusted Remove Home Health and Hospice Segment Results Encompass Health As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 240.2 $ — $ — $ — $ — $ 240.2 $ (43.8) $ 196.4 Depreciation and amortization (68.8) — — — — (68.8) 8.2 (60.6) Interest expense and amortization of debt discounts and fees (60.6) — — 20.5 — (40.1) 0.1 (40.0) Stock-based compensation (8.8) — — — — (8.8) 1.2 (7.6) Loss on disposal or impairment of assets (2.3) — — — — (2.3) (0.4) (2.7) Loss on early extinguishment of debt(1) (1.1) 1.1 — — — — — — Costs associated with the strategic alternatives review (22.9) — — 22.9 — — — — Change in fair market value of equity securities (3.2) — — — 3.2 — — — Income from continuing operations before income tax expense 72.5 1.1 — 43.4 3.2 120.2 (34.7) 85.5 Provision for income tax expense (23.8) (0.3) 5.5 (11.3) (0.9) (30.8) 7.5 (23.3) Income from continuing operations attributable to Encompass Health $ 48.7 $ 0.8 $ 5.5 $ 32.1 $ 2.3 $ 89.4 $ (27.2) $ 62.2 Diluted earnings per share from continuing operations* $ 0.49 $ 0.01 $ 0.05 $ 0.32 $ 0.02 $ 0.89 $ (0.27) $ 0.62 Diluted shares used in calculation 100.3 * Adjusted EPS may not sum across due to rounding. Refer to pages 43-44 for end notes.

 
Encompass Health 40 For the Three Months Ended June 30, 2021 Adjustments As Reported Loss on Early Exting. of Debt Income Tax Adjustments Costs Associated with the Strategic Alternatives Review Costs Associated with the Frontier Acquisition Change in Fair Market Value of Equity Securities Consolidated As Adjusted Remove Home Health and Hospice Segment Results Encompass Health As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 278.9 $ — $ — $ — $ — $ — $ 278.9 $ (61.7) $ 217.2 Depreciation and amortization (63.4) — — — — — (63.4) 9.4 (54.0) Interest expense and amortization of debt discounts and fees (41.8) — — — — — (41.8) 0.1 (41.7) Stock-based compensation (12.0) — — — — — (12.0) 1.2 (10.8) Loss on disposal or impairment of assets (2.9) — — — — — (2.9) (0.4) (3.3) Loss on early extinguishment of debt(2) (1.0) 1.0 — — — — — — — Costs associated with the strategic alternatives review (4.1) — — 4.1 — — — — — Costs associated with the Frontier acquisition (1.3) — — — 1.3 — — — — Change in fair market value of equity securities 0.7 — — — — (0.7) — — — Income from continuing operations before income tax expense 153.1 1.0 — 4.1 1.3 (0.7) 158.8 (51.4) 107.4 Provision for income tax expense (39.5) (0.3) (0.1) (1.1) (0.3) 0.2 (41.1) 12.6 (28.5) Income from continuing operations attributable to Encompass Health $ 113.6 $ 0.7 $ (0.1) $ 3.0 $ 1.0 $ (0.5) $ 117.7 $ (38.8) $ 78.9 Diluted earnings per share from continuing operations* $ 1.13 $ 0.01 $ — $ 0.03 $ 0.01 $ — $ 1.17 $ (0.39) $ 0.79 Diluted shares used in calculation 100.2 Adjusted EPS(4) - Q2 2021 * Adjusted EPS may not sum across due to rounding. Refer to pages 43-44 for end notes.

 
Encompass Health 41 Adjusted EPS(4) - YTD Q2 2022 For the Six Months Ended June 30, 2022 Adjustments As Reported Loss on Early Exting. of Debt Income Tax Adjustments Costs Associated with the Strategic Alternatives Review Change in Fair Market Value of Equity Securities Consolidated As Adjusted Remove Home Health and Hospice Segment Results Encompass Health As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 485.2 $ — $ — $ — $ — $ 485.2 $ (93.8) $ 391.4 Depreciation and amortization (135.0) — — — — (135.0) 16.7 (118.3) Interest expense and amortization of debt discounts and fees (100.2) — — 20.5 — (79.7) 0.1 (79.6) Stock-based compensation (16.3) — — — — (16.3) 2.5 (13.8) Loss on disposal or impairment of assets (2.9) — — — — (2.9) (0.5) (3.4) Loss on early extinguishment of debt(1)(3) (1.4) 1.4 — — — — — — Costs associated with the strategic alternatives review (32.5) — — 32.5 — — — — Change in fair market value of equity securities (5.7) — — — 5.7 — — — Income from continuing operations before income tax expense 191.2 1.4 — 53.0 5.7 251.3 (75.0) 176.3 Provision for income tax expense (55.0) (0.4) 5.7 (13.8) (1.5) (65.0) 17.0 (48.0) Income from continuing operations attributable to Encompass Health $ 136.2 $ 1.0 $ 5.7 $ 39.2 $ 4.2 $ 186.3 $ (58.0) $ 128.3 Diluted earnings per share from continuing operations* $ 1.36 $ 0.01 $ 0.06 $ 0.39 $ 0.04 $ 1.86 $ (0.58) $ 1.28 Diluted shares used in calculation 100.2 * Adjusted EPS may not sum across due to rounding. Refer to pages 43-44 for end notes.

 
Encompass Health 42 For the Six Months Ended June 30, 2021 Adjustments As Reported Loss on Early Exting. of Debt Income Tax Adjustments Costs Associated with the Strategic Alternatives Review Costs Associated with the Frontier Acquisition Change in Fair Market Value of Equity Securities Consolidated As Adjusted Remove Home Health and Hospice Segment Results Encompass Health As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 529.7 $ — $ — $ — $ — $ — $ 529.7 $ (112.5) $ 417.2 Depreciation and amortization (125.9) — — — — — (125.9) 18.5 (107.4) Interest expense and amortization of debt discounts and fees (84.6) — — — — — (84.6) 0.1 (84.5) Stock-based compensation (14.8) — — — — — (14.8) 1.8 (13.0) Loss on disposal or impairment of assets (2.8) — — — — — (2.8) (0.5) (3.3) Loss on early extinguishment of debt(2) (1.0) 1.0 — — — — — — — Costs associated with the strategic alternatives review (5.0) — — 5.0 — — — — — Costs associated with the Frontier acquisition (1.3) — — — 1.3 — — — — Change in fair market value of equity securities 0.6 — — — — (0.6) — — — Income from continuing operations before income tax expense 294.9 1.0 — 5.0 1.3 (0.6) 301.6 (92.6) 209.0 Provision for income tax expense (74.0) (0.3) (3.4) (1.3) (0.3) 0.2 (79.1) 22.4 (56.7) Income from continuing operations attributable to Encompass Health $ 220.9 $ 0.7 $ (3.4) $ 3.7 $ 1.0 $ (0.4) $ 222.5 $ (70.2) $ 152.3 Diluted earnings per share from continuing operations* $ 2.20 $ 0.01 $ (0.03) $ 0.04 $ 0.01 $ — $ 2.22 $ (0.70) $ 1.52 Diluted shares used in calculation 100.2 Adjusted EPS(4) - YTD Q2 2021 * Adjusted EPS may not sum across due to rounding. Refer to pages 43-44 for end notes.

 
Encompass Health 43 End notes (1) In the second quarter of 2022, the Company redeemed approximately $236 million of its term loan due 2024 and fully repaid the $250 million outstanding balance on its revolving credit facility. The redemption was completed using proceeds which were dividended from Enhabit. As a result of the redemption, the Company recorded a $1.1 million loss on early extinguishment of debt in the second quarter of 2022. (2) In the second quarter of 2021, the Company redeemed a total of $200 million of 5.125% Senior Notes due 2023 ($100 million in April and $100 million in June). The redemptions were completed at 100% of par using cash on hand and drawings under the Company’s revolving credit facility. As a result of the redemptions, the Company recorded a $1.0 million loss on early extinguishment of debt in the second quarter of 2021. (3) In the first quarter of 2022, the Company redeemed the remaining $100 million of its 5.125% Senior Notes due 2023. The redemption was completed at 100% of par using drawings under the Company’s revolving credit facility. As a result of the redemption, the Company recorded a $0.3 million loss on early extinguishment of debt in the first quarter of 2022. (4) The Company is providing adjusted earnings per share from continuing operations attributable to Encompass Health (“adjusted earnings per share”), which is a non-GAAP measure. The Company believes the presentation of adjusted earnings per share provides useful additional information to investors because it provides better comparability of ongoing operating performance to prior periods given that it excludes the impact of government, class action, and related settlements, professional fees - accounting, tax, and legal, mark-to-market adjustments for stock appreciation rights, gains or losses related to hedging and equity instruments, loss on early extinguishment of debt, adjustments to its income tax provision (such as valuation allowance adjustments, settlements of income tax claims and windfall tax benefits), items related to corporate and facility restructurings, and certain other items deemed to be non-indicative of ongoing operating performance. It is reasonable to expect that one or more of these excluded items will occur in future periods, but the amounts recognized can vary significantly from period to period and may not directly relate to the Company's ongoing operating performance. Accordingly, they can complicate comparisons of the Company's results of operations across periods and comparisons of the Company's results to those of other healthcare companies. Adjusted earnings per share should not be considered as a measure of financial performance under generally accepted accounting principles in the United States as the items excluded from it are significant components in understanding and assessing financial performance. Because adjusted earnings per share is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies.* (5) Definition of adjusted free cash flow, which is a non-GAAP measure, is net cash provided by operating activities of continuing operations minus capital expenditures for maintenance, dividends paid on preferred stock, distributions to noncontrolling interests, and certain other items deemed to be non- indicative of ongoing operating performance. Common stock dividends are not included in the calculation of adjusted free cash flow. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. (6) Adjusted EBITDA is a non-GAAP financial measure. The Company’s leverage ratio (total consolidated debt to Adjusted EBITDA for the trailing four quarters) is, likewise, a non-GAAP measure. Management and some members of the investment community utilize Adjusted EBITDA as a financial measure and the leverage ratio as a liquidity measure on an ongoing basis. These measures are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance or liquidity. In evaluating Adjusted EBITDA, the reader should be aware that in the future the Company may incur expenses similar to the adjustments set forth. (7) On Oct. 28, 2013, the Company announced its board of directors authorized the repurchase of up to $200 million of its common stock. On Feb. 14, 2014, the Company's board approved an increase in this common stock repurchase authorization from $200 million to $250 million. As of June 30, 2018, the remaining repurchase authorization was approximately $58 million. On July 24, 2018, the Company's board approved resetting the aggregate common stock repurchase authorization to $250 million. As of June 30, 2022, the remaining repurchase authorization was approximately $198 million. (8) As a result of negotiations with our partner to amend the joint venture agreement related to Yuma Rehabilitation Hospital, the accounting for this hospital changed from the equity method of accounting to a consolidated entity effective July 1, 2019. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. As a result of our consolidation of this hospital and the remeasurement of our previously held equity interest at fair value, we recorded a $19.2 million gain as part of other income in the third quarter of 2019. (9) Data provided by Uniform Data System for Medical Rehabilitation, a division of UB Foundation Activities, Inc., a data gathering and analysis organization for the rehabilitation industry; represents ~80% of industry, including Encompass Health inpatient rehabilitation sites. * Reconciliations to GAAP provided on pages 35-42.

 
Encompass Health 44 End notes, continued (10) Represents discharges from 150 consolidated hospitals in Q2 2022; 147 consolidated hospitals in Q1 2022; 145 consolidated hospitals in Q4 2021; 144 consolidated hospitals in Q3 2021; 140 consolidated hospitals in Q2 2021; and 138 consolidated hospitals in Q1 2021. (11) Full-time equivalents included in the table represent Encompass Health employees who participate in or support the operations of our hospitals and include an estimate of full-time equivalents related to contract labor. (12) Employees per occupied bed, or “EPOB,” is calculated by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by the Company’s occupancy percentage. (13) As a result of an amendment to the joint venture agreement related to our home health location in Boynton Beach, Florida, the accounting for this agency changed from the equity method of accounting to a consolidated entity effective December 1, 2021. We accounted for this change in control as a business combination and consolidated this entity using the acquisition method. As a result of our consolidation of this agency and the remeasurement of our previously held equity interest at fair value, we recorded a $3.2 million gain as part of other income in the fourth quarter of 2021.